Your browser doesn't support javascript.
loading
In vivo imaging of microenvironmental and anti-PD-L1-mediated dynamics in cancer using S100A8/S100A9 as an imaging biomarker.
Helfen, Anne; Rieß, Jan; Fehler, Olesja; Stölting, Miriam; An, Zhengwen; Kocman, Vanessa; Schnepel, Annika; Geyer, Christiane; Gerwing, Mirjam; Masthoff, Max; Vogl, Thomas; Höltke, Carsten; Roth, Johannes; Ng, Tony; Wildgruber, Moritz; Eisenblätter, Michel.
Afiliación
  • Helfen A; Department of Radiology, University Hospital Muenster, University of Muenster, D-48149 Muenster, Germany. Electronic address: anne.helfen@ukmuenster.de.
  • Rieß J; Department of Radiology, University Hospital Muenster, University of Muenster, D-48149 Muenster, Germany.
  • Fehler O; Institute of Immunology, University of Muenster, D-48149 Muenster, Germany.
  • Stölting M; Department of Radiology, University Hospital Muenster, University of Muenster, D-48149 Muenster, Germany.
  • An Z; The CRUK City of London Cancer Centre, SE1 9RT London, UK.
  • Kocman V; Department of Radiology, University Hospital Muenster, University of Muenster, D-48149 Muenster, Germany.
  • Schnepel A; Department of Radiology, University Hospital Muenster, University of Muenster, D-48149 Muenster, Germany.
  • Geyer C; Department of Radiology, University Hospital Muenster, University of Muenster, D-48149 Muenster, Germany.
  • Gerwing M; Department of Radiology, University Hospital Muenster, University of Muenster, D-48149 Muenster, Germany.
  • Masthoff M; Department of Radiology, University Hospital Muenster, University of Muenster, D-48149 Muenster, Germany.
  • Vogl T; Institute of Immunology, University of Muenster, D-48149 Muenster, Germany.
  • Höltke C; Department of Radiology, University Hospital Muenster, University of Muenster, D-48149 Muenster, Germany.
  • Roth J; Institute of Immunology, University of Muenster, D-48149 Muenster, Germany.
  • Ng T; The CRUK City of London Cancer Centre, SE1 9RT London, UK; UCL Cancer Institute, University College London, SE1 9RT London, UK; School of Cancer and Pharmaceutical Sciences, King´s College London, SE1 9RT London, UK.
  • Wildgruber M; Department of Radiology, University Hospital Muenster, University of Muenster, D-48149 Muenster, Germany; Department for Radiology, LMU Munich, D-81377 Munich, Germany.
  • Eisenblätter M; Department of Radiology, University Hospital Muenster, University of Muenster, D-48149 Muenster, Germany; Department of Diagnostic and Interventional Radiology, Medical Center - University of Freiburg, D-79106 Freiburg, Germany.
Neoplasia ; 28: 100792, 2022 06.
Article en En | MEDLINE | ID: mdl-35367789
PURPOSE: As a promotor of tumor invasion and tumor microenvironment (TME) formation, the protein complex S100A8/S100A9 is associated with poor prognosis. Our aim was to further evaluate its origin and regulatory effects, and to establish an imaging biomarker for TME activity. METHODS: S100A9-/-cells (ko) were created from syngeneic murine breast cancer 4T1 (high malignancy) and 67NR (low malignancy) wildtype (wt) cell lines and implanted into either female BALB/c wildtype or S100A9-/- mice (n = 10 each). Anti-S100A9-Cy5.5-targeted fluorescence reflectance imaging was performed at 0 h and 24 h after injection. Potential early changes of S100A9-presence under immune checkpoint inhibition (anti-PD-L1, n = 7 vs. rat IgG2b as isotype control, n = 3) were evaluated. RESULTS: In S100A9-/-mice contrast-to-noise-ratios were significantly reduced for wt and S100A9-/-tumors. No significant differences were detected for 4T1 ko and 67NR ko cells as compared to wildtype cells. Under anti-PD-L1 treatment S100A9 presence significantly decreased compared with the control group. CONCLUSION: Our results confirm a secretion of S100A8/S100A9 by the TME, while tumor cells do not apparently release the protein. Under immune checkpoint inhibition S100A9-imaging reports an early decrease of TME activity. Therefore, S100A9-specific imaging may serve as an imaging biomarker for TME formation and activity.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Inhibidores de Puntos de Control Inmunológico Límite: Animals / Female / Humans Idioma: En Revista: Neoplasia Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Inhibidores de Puntos de Control Inmunológico Límite: Animals / Female / Humans Idioma: En Revista: Neoplasia Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos